Detalhe da pesquisa
1.
Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinib.
Br J Haematol
; 201(5): 897-904, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36626914
2.
Immunopathology of Hyperinflammation in COVID-19.
Am J Pathol
; 191(1): 4-17, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32919977
3.
Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy.
Haematologica
; 107(5): 1163-1171, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34162182
4.
Predictive factors of outcomes in patients with AL amyloidosis treated with daratumumab.
Am J Hematol
; 97(1): 79-89, 2022 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34739735
5.
Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study.
Am J Hematol
; 97(9): 1189-1199, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35731907
6.
Bone marrow involvement and subclonal diversity impairs detection of mutated CXCR4 by diagnostic next-generation sequencing in Waldenström macroglobulinaemia.
Br J Haematol
; 194(4): 730-733, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33713429
7.
Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib.
Br J Haematol
; 192(3): 542-550, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33207010
8.
BTKCys481Ser drives ibrutinib resistance via ERK1/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism.
Blood
; 131(18): 2047-2059, 2018 05 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29496671
9.
Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia.
Am J Hematol
; 95(4): 372-378, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31868242
10.
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenström macroglobulinaemia treated with ibrutinib.
Br J Haematol
; 187(3): 356-363, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31267520
11.
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.
Br J Haematol
; 184(2): 242-245, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30183082
12.
Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.
Blood
; 129(18): 2519-2525, 2017 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28235842
13.
Cell Wall Hydrolytic Enzymes Enhance Antimicrobial Drug Activity Against Mycobacterium.
Curr Microbiol
; 76(4): 398-409, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30603964
14.
Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia.
Br J Haematol
; 181(1): 77-85, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29468652
15.
MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.
Br J Haematol
; 180(3): 374-380, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29181840
16.
Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.
Blood
; 128(6): 827-38, 2016 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27301862
17.
Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes.
Haematologica
; 108(6): 1680-1684, 2023 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36546447
18.
Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound.
Am J Hematol
; 93(4): 511-517, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29280186
19.
Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia.
Br J Haematol
; 177(5): 717-725, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28485115
20.
IgM myeloma: A multicenter retrospective study of 134 patients.
Am J Hematol
; 92(8): 746-751, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28383205